Eli Lilly expects to be among top 20 pharma companies in India by 2020
The US-based drug firm is looking for a wide presence in India.
New Delhi, June 9, 2013: The US-based pharma company, Eli Lilly expects to be among the top 20 pharma companies in India by 2020. The company is aiming to strengthen its presence in core segments like diabetes, oncology, cardiovascular and neuro sciences. The company is currently at the 50th position and aims to break into the top 20 within the next seven years.
The company aims to expand its existing product portfolio and also launch new products in order to achieve its target.
It may be noted here that as part of its strategy, the company plans to launch its innovative insulin delivery device 'Savvio' in Indian market by August 2013. The company also plans to increase its workforce from the current 400 in the country.